Data from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer Article Swipe
Raquel De Souza
,
Payam Zahedi
,
Rose M. Badame
,
Christine Allen
,
Micheline Piquette‐Miller
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.c.6535234
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.c.6535234
Drug resistance leads to chemotherapy failure and is responsible for the death of a great majority of patients with metastatic, late-stage ovarian cancer. The present study addressed whether changes in the chemotherapy dosing schedule affect the development, further worsening, or circumvention of drug resistance in chemosensitive and chemoresistant ovarian cancer. Severe combined immunodeficient mice bearing HeyA8 and HeyA8-MDR xenografts were treated with docetaxel intermittently (1×/wk or 3×/wk) or continuously for 21 days. Tumor mRNA expression of genes implicated in docetaxel resistance was measured by quantitative real-time-PCR. Analyzed genes included those encoding for the drug efflux transporters mdr1 and mrp7 and for molecules that interfere with or overcome the effects of docetaxel, including β-tubulinIII, actinin4, stathmin1, bcl2, rpn2, thoredoxin, and akt2. In both models, continuous docetaxel resulted in greater antitumor efficacy than 1×/wk or 3×/wk dosing and did not induce upregulation of any analyzed genes. Once weekly dosing caused upregulation of various drug resistance–related genes, especially in chemoresistant xenografts. More frequent, 3×/wk dosing diminished this effect, although levels of various genes were higher than for continuous chemotherapy. Drug efflux transporter expression was further examined by Western blotting, confirming that intermittent, but not continuous, docetaxel induced significant upregulation. Overall, our results show that the presence and length of treatment-free intervals contribute to the development of drug resistance. Elimination of these intervals by continuous dosing resulted in superior antitumor efficacy and prevented drug resistance induction in chemosensitive and chemoresistant disease. These results encourage the clinical implementation of continuous chemotherapy to overcome and/or prevent drug resistance in newly diagnosed and recurrent, refractory ovarian cancer. Mol Cancer Ther; 10(7); 1289–99. ©2011 AACR.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1535-7163.c.6535234
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4362478863
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4362478863Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1535-7163.c.6535234Digital Object Identifier
- Title
-
Data from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian CancerWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-04-03Full publication date if available
- Authors
-
Raquel De Souza, Payam Zahedi, Rose M. Badame, Christine Allen, Micheline Piquette‐MillerList of authors in order
- Landing page
-
https://doi.org/10.1158/1535-7163.c.6535234Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1535-7163.c.6535234Direct OA link when available
- Concepts
-
Docetaxel, Chemotherapy, Dosing, Pharmacology, Downregulation and upregulation, Medicine, Ovarian cancer, Efflux, Cancer, Drug resistance, Cisplatin, Internal medicine, Cancer research, Biology, Gene, Biochemistry, Microbiology, GeneticsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4362478863 |
|---|---|
| doi | https://doi.org/10.1158/1535-7163.c.6535234 |
| ids.doi | https://doi.org/10.1158/1535-7163.c.6535234 |
| ids.openalex | https://openalex.org/W4362478863 |
| fwci | |
| type | preprint |
| title | Data from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10550 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9990000128746033 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2743 |
| topics[0].subfield.display_name | Reproductive Medicine |
| topics[0].display_name | Ovarian cancer diagnosis and treatment |
| topics[1].id | https://openalex.org/T11287 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9940999746322632 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1306 |
| topics[1].subfield.display_name | Cancer Research |
| topics[1].display_name | Cancer Genomics and Diagnostics |
| topics[2].id | https://openalex.org/T11845 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9930999875068665 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Cancer therapeutics and mechanisms |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2781190966 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8820853233337402 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q420436 |
| concepts[0].display_name | Docetaxel |
| concepts[1].id | https://openalex.org/C2776694085 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6260982751846313 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[1].display_name | Chemotherapy |
| concepts[2].id | https://openalex.org/C2777288759 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6234704256057739 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q4164182 |
| concepts[2].display_name | Dosing |
| concepts[3].id | https://openalex.org/C98274493 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6032648682594299 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[3].display_name | Pharmacology |
| concepts[4].id | https://openalex.org/C127561419 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5946590900421143 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q224527 |
| concepts[4].display_name | Downregulation and upregulation |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.5081419944763184 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C2780427987 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5028607249259949 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q172341 |
| concepts[6].display_name | Ovarian cancer |
| concepts[7].id | https://openalex.org/C200082930 |
| concepts[7].level | 2 |
| concepts[7].score | 0.5028002262115479 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q22327148 |
| concepts[7].display_name | Efflux |
| concepts[8].id | https://openalex.org/C121608353 |
| concepts[8].level | 2 |
| concepts[8].score | 0.49803590774536133 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[8].display_name | Cancer |
| concepts[9].id | https://openalex.org/C114851261 |
| concepts[9].level | 2 |
| concepts[9].score | 0.46106916666030884 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12147416 |
| concepts[9].display_name | Drug resistance |
| concepts[10].id | https://openalex.org/C2778239845 |
| concepts[10].level | 3 |
| concepts[10].score | 0.4347066581249237 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q412415 |
| concepts[10].display_name | Cisplatin |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3610454797744751 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| concepts[12].id | https://openalex.org/C502942594 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3529794216156006 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[12].display_name | Cancer research |
| concepts[13].id | https://openalex.org/C86803240 |
| concepts[13].level | 0 |
| concepts[13].score | 0.26646000146865845 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[13].display_name | Biology |
| concepts[14].id | https://openalex.org/C104317684 |
| concepts[14].level | 2 |
| concepts[14].score | 0.18679329752922058 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[14].display_name | Gene |
| concepts[15].id | https://openalex.org/C55493867 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[15].display_name | Biochemistry |
| concepts[16].id | https://openalex.org/C89423630 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[16].display_name | Microbiology |
| concepts[17].id | https://openalex.org/C54355233 |
| concepts[17].level | 1 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[17].display_name | Genetics |
| keywords[0].id | https://openalex.org/keywords/docetaxel |
| keywords[0].score | 0.8820853233337402 |
| keywords[0].display_name | Docetaxel |
| keywords[1].id | https://openalex.org/keywords/chemotherapy |
| keywords[1].score | 0.6260982751846313 |
| keywords[1].display_name | Chemotherapy |
| keywords[2].id | https://openalex.org/keywords/dosing |
| keywords[2].score | 0.6234704256057739 |
| keywords[2].display_name | Dosing |
| keywords[3].id | https://openalex.org/keywords/pharmacology |
| keywords[3].score | 0.6032648682594299 |
| keywords[3].display_name | Pharmacology |
| keywords[4].id | https://openalex.org/keywords/downregulation-and-upregulation |
| keywords[4].score | 0.5946590900421143 |
| keywords[4].display_name | Downregulation and upregulation |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.5081419944763184 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/ovarian-cancer |
| keywords[6].score | 0.5028607249259949 |
| keywords[6].display_name | Ovarian cancer |
| keywords[7].id | https://openalex.org/keywords/efflux |
| keywords[7].score | 0.5028002262115479 |
| keywords[7].display_name | Efflux |
| keywords[8].id | https://openalex.org/keywords/cancer |
| keywords[8].score | 0.49803590774536133 |
| keywords[8].display_name | Cancer |
| keywords[9].id | https://openalex.org/keywords/drug-resistance |
| keywords[9].score | 0.46106916666030884 |
| keywords[9].display_name | Drug resistance |
| keywords[10].id | https://openalex.org/keywords/cisplatin |
| keywords[10].score | 0.4347066581249237 |
| keywords[10].display_name | Cisplatin |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.3610454797744751 |
| keywords[11].display_name | Internal medicine |
| keywords[12].id | https://openalex.org/keywords/cancer-research |
| keywords[12].score | 0.3529794216156006 |
| keywords[12].display_name | Cancer research |
| keywords[13].id | https://openalex.org/keywords/biology |
| keywords[13].score | 0.26646000146865845 |
| keywords[13].display_name | Biology |
| keywords[14].id | https://openalex.org/keywords/gene |
| keywords[14].score | 0.18679329752922058 |
| keywords[14].display_name | Gene |
| language | en |
| locations[0].id | doi:10.1158/1535-7163.c.6535234 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1535-7163.c.6535234 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5057874572 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5502-6329 |
| authorships[0].author.display_name | Raquel De Souza |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Raquel De Souza |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5033070603 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6636-4534 |
| authorships[1].author.display_name | Payam Zahedi |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Payam Zahedi |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5015151704 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Rose M. Badame |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Rose M. Badame |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5086834252 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-4916-3965 |
| authorships[3].author.display_name | Christine Allen |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Christine Allen |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5013796776 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-3847-8224 |
| authorships[4].author.display_name | Micheline Piquette‐Miller |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Micheline Piquette-Miller |
| authorships[4].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1535-7163.c.6535234 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10550 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9990000128746033 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2743 |
| primary_topic.subfield.display_name | Reproductive Medicine |
| primary_topic.display_name | Ovarian cancer diagnosis and treatment |
| related_works | https://openalex.org/W4233456208, https://openalex.org/W2891028327, https://openalex.org/W2378605750, https://openalex.org/W2374947457, https://openalex.org/W3030062260, https://openalex.org/W13394025, https://openalex.org/W2371287473, https://openalex.org/W2122691344, https://openalex.org/W2324380568, https://openalex.org/W2512319950 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1535-7163.c.6535234 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1535-7163.c.6535234 |
| primary_location.id | doi:10.1158/1535-7163.c.6535234 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1535-7163.c.6535234 |
| publication_date | 2023-04-03 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 13 |
| abstract_inverted_index.21 | 70 |
| abstract_inverted_index.In | 120 |
| abstract_inverted_index.by | 83, 183, 219 |
| abstract_inverted_index.in | 29, 44, 78, 126, 155, 223, 232, 252 |
| abstract_inverted_index.is | 7 |
| abstract_inverted_index.of | 12, 16, 41, 75, 109, 140, 149, 167, 205, 212, 216, 243 |
| abstract_inverted_index.or | 39, 65, 67, 105, 132 |
| abstract_inverted_index.to | 3, 209, 246 |
| abstract_inverted_index.The | 23 |
| abstract_inverted_index.and | 6, 46, 56, 97, 99, 118, 135, 203, 227, 234, 255 |
| abstract_inverted_index.any | 141 |
| abstract_inverted_index.but | 189 |
| abstract_inverted_index.did | 136 |
| abstract_inverted_index.for | 9, 69, 91, 100, 173 |
| abstract_inverted_index.not | 137, 190 |
| abstract_inverted_index.our | 197 |
| abstract_inverted_index.the | 10, 30, 35, 92, 107, 201, 210, 240 |
| abstract_inverted_index.was | 81, 180 |
| abstract_inverted_index.Drug | 176 |
| abstract_inverted_index.More | 158 |
| abstract_inverted_index.Once | 144 |
| abstract_inverted_index.both | 121 |
| abstract_inverted_index.drug | 42, 93, 151, 213, 229, 250 |
| abstract_inverted_index.mRNA | 73 |
| abstract_inverted_index.mice | 53 |
| abstract_inverted_index.show | 199 |
| abstract_inverted_index.than | 130, 172 |
| abstract_inverted_index.that | 102, 187, 200 |
| abstract_inverted_index.this | 163 |
| abstract_inverted_index.were | 59, 170 |
| abstract_inverted_index.with | 18, 61, 104 |
| abstract_inverted_index.HeyA8 | 55 |
| abstract_inverted_index.Ther; | 262 |
| abstract_inverted_index.These | 237 |
| abstract_inverted_index.Tumor | 72 |
| abstract_inverted_index.days. | 71 |
| abstract_inverted_index.death | 11 |
| abstract_inverted_index.genes | 76, 87, 169 |
| abstract_inverted_index.great | 14 |
| abstract_inverted_index.leads | 2 |
| abstract_inverted_index.newly | 253 |
| abstract_inverted_index.study | 25 |
| abstract_inverted_index.these | 217 |
| abstract_inverted_index.those | 89 |
| abstract_inverted_index.10(7); | 263 |
| abstract_inverted_index.1×/wk | 131 |
| abstract_inverted_index.3×/wk | 133, 160 |
| abstract_inverted_index.Cancer | 261 |
| abstract_inverted_index.Severe | 50 |
| abstract_inverted_index.affect | 34 |
| abstract_inverted_index.and/or | 248 |
| abstract_inverted_index.caused | 147 |
| abstract_inverted_index.dosing | 32, 134, 146, 161, 221 |
| abstract_inverted_index.efflux | 94, 177 |
| abstract_inverted_index.genes, | 153 |
| abstract_inverted_index.genes. | 143 |
| abstract_inverted_index.higher | 171 |
| abstract_inverted_index.induce | 138 |
| abstract_inverted_index.length | 204 |
| abstract_inverted_index.levels | 166 |
| abstract_inverted_index.weekly | 145 |
| abstract_inverted_index.©2011 | 265 |
| abstract_inverted_index.(1×/wk | 64 |
| abstract_inverted_index.3×/wk) | 66 |
| abstract_inverted_index.Western | 184 |
| abstract_inverted_index.bearing | 54 |
| abstract_inverted_index.cancer. | 22, 49, 259 |
| abstract_inverted_index.changes | 28 |
| abstract_inverted_index.effect, | 164 |
| abstract_inverted_index.effects | 108 |
| abstract_inverted_index.failure | 5 |
| abstract_inverted_index.further | 37, 181 |
| abstract_inverted_index.greater | 127 |
| abstract_inverted_index.induced | 193 |
| abstract_inverted_index.models, | 122 |
| abstract_inverted_index.ovarian | 21, 48, 258 |
| abstract_inverted_index.present | 24 |
| abstract_inverted_index.prevent | 249 |
| abstract_inverted_index.results | 198, 238 |
| abstract_inverted_index.treated | 60 |
| abstract_inverted_index.various | 150, 168 |
| abstract_inverted_index.whether | 27 |
| abstract_inverted_index.Analyzed | 86 |
| abstract_inverted_index.Overall, | 196 |
| abstract_inverted_index.although | 165 |
| abstract_inverted_index.analyzed | 142 |
| abstract_inverted_index.clinical | 241 |
| abstract_inverted_index.combined | 51 |
| abstract_inverted_index.disease. | 236 |
| abstract_inverted_index.efficacy | 129, 226 |
| abstract_inverted_index.encoding | 90 |
| abstract_inverted_index.examined | 182 |
| abstract_inverted_index.included | 88 |
| abstract_inverted_index.majority | 15 |
| abstract_inverted_index.measured | 82 |
| abstract_inverted_index.overcome | 106, 247 |
| abstract_inverted_index.patients | 17 |
| abstract_inverted_index.presence | 202 |
| abstract_inverted_index.resulted | 125, 222 |
| abstract_inverted_index.schedule | 33 |
| abstract_inverted_index.superior | 224 |
| abstract_inverted_index.HeyA8-MDR | 57 |
| abstract_inverted_index.addressed | 26 |
| abstract_inverted_index.antitumor | 128, 225 |
| abstract_inverted_index.blotting, | 185 |
| abstract_inverted_index.diagnosed | 254 |
| abstract_inverted_index.docetaxel | 62, 79, 124, 192 |
| abstract_inverted_index.encourage | 239 |
| abstract_inverted_index.frequent, | 159 |
| abstract_inverted_index.including | 111 |
| abstract_inverted_index.induction | 231 |
| abstract_inverted_index.interfere | 103 |
| abstract_inverted_index.intervals | 207, 218 |
| abstract_inverted_index.molecules | 101 |
| abstract_inverted_index.prevented | 228 |
| abstract_inverted_index.1289–99. | 264 |
| abstract_inverted_index.confirming | 186 |
| abstract_inverted_index.continuous | 123, 174, 220, 244 |
| abstract_inverted_index.contribute | 208 |
| abstract_inverted_index.diminished | 162 |
| abstract_inverted_index.docetaxel, | 110 |
| abstract_inverted_index.especially | 154 |
| abstract_inverted_index.expression | 74, 179 |
| abstract_inverted_index.implicated | 77 |
| abstract_inverted_index.late-stage | 20 |
| abstract_inverted_index.recurrent, | 256 |
| abstract_inverted_index.refractory | 257 |
| abstract_inverted_index.resistance | 1, 43, 80, 230, 251 |
| abstract_inverted_index.worsening, | 38 |
| abstract_inverted_index.xenografts | 58 |
| abstract_inverted_index.Elimination | 215 |
| abstract_inverted_index.continuous, | 191 |
| abstract_inverted_index.development | 211 |
| abstract_inverted_index.metastatic, | 19 |
| abstract_inverted_index.resistance. | 214 |
| abstract_inverted_index.responsible | 8 |
| abstract_inverted_index.significant | 194 |
| abstract_inverted_index.transporter | 178 |
| abstract_inverted_index.xenografts. | 157 |
| abstract_inverted_index.<i>Mol | 260 |
| abstract_inverted_index.chemotherapy | 4, 31, 245 |
| abstract_inverted_index.continuously | 68 |
| abstract_inverted_index.development, | 36 |
| abstract_inverted_index.quantitative | 84 |
| abstract_inverted_index.transporters | 95 |
| abstract_inverted_index.upregulation | 139, 148 |
| abstract_inverted_index.chemotherapy. | 175 |
| abstract_inverted_index.circumvention | 40 |
| abstract_inverted_index.intermittent, | 188 |
| abstract_inverted_index.upregulation. | 195 |
| abstract_inverted_index.chemoresistant | 47, 156, 235 |
| abstract_inverted_index.chemosensitive | 45, 233 |
| abstract_inverted_index.implementation | 242 |
| abstract_inverted_index.intermittently | 63 |
| abstract_inverted_index.real-time-PCR. | 85 |
| abstract_inverted_index.treatment-free | 206 |
| abstract_inverted_index.immunodeficient | 52 |
| abstract_inverted_index.resistance–related | 152 |
| abstract_inverted_index.<i>mdr1</i> | 96 |
| abstract_inverted_index.<i>mrp7</i> | 98 |
| abstract_inverted_index.<i>akt2</i>. | 119 |
| abstract_inverted_index.<i>bcl2</i>, | 115 |
| abstract_inverted_index.<i>rpn2</i>, | 116 |
| abstract_inverted_index.<i>actinin4</i>, | 113 |
| abstract_inverted_index.<i>stathmin1</i>, | 114 |
| abstract_inverted_index.<i>thoredoxin</i>, | 117 |
| abstract_inverted_index.<div>Abstract<p>Drug | 0 |
| abstract_inverted_index.<i>β-tubulinIII</i>, | 112 |
| abstract_inverted_index.AACR</i>.</p></div> | 266 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 5 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8700000047683716 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.12663511 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |